Six PAH patients who are WHO functional class II or III and on stable PAH therapy for at least 4 months will be treated with olaparib 400 mg twice daily for 16 weeks, with the primary end point being change in PVR stromectol 12mg To test whether a similar interaction in luminal cells affects the expression of p53 target genes that influence survival and apoptosis, we analyzed ERО± positive T47D cells that express mutant p53